<DOC>
	<DOCNO>NCT00001001</DOCNO>
	<brief_summary>To examine pharmacokinetics ( blood level ) bioavailability zidovudine ( AZT ) give patient HIV infection chronic liver disease . The specific aim study provide data permit development guideline use AZT patient mild , moderate , severe liver disease . AZT antiviral agent show effective patient severe HIV infection . However , AZT largely eliminate body biochemical reaction take place liver , possible patient underlie liver disease may alter AZT pharmacokinetics may metabolize AZT differently , result susceptible increase risk serious drug toxicity . This study examine pharmacokinetics , elimination , metabolism AZT patient liver disease . Guidelines develop data helpful manage AZT treatment HIV-infected person indicate whether dose AZT administer adjust compensate change bioavailability and/or pharmacokinetics .</brief_summary>
	<brief_title>A Study Zidovudine HIV-Infected Patients With Liver Disease</brief_title>
	<detailed_description>AZT antiviral agent show effective patient severe HIV infection . However , AZT largely eliminate body biochemical reaction take place liver , possible patient underlie liver disease may alter AZT pharmacokinetics may metabolize AZT differently , result susceptible increase risk serious drug toxicity . This study examine pharmacokinetics , elimination , metabolism AZT patient liver disease . Guidelines develop data helpful manage AZT treatment HIV-infected person indicate whether dose AZT administer adjust compensate change bioavailability and/or pharmacokinetics . Patients assess stratified accord liver function severity liver disease . Patients receive intravenous ( IV ) dose AZT first day study , follow oral dose 24 hour later second day study . Patients fast 8 hour prior dose 2 hour dose . Liver function test repeat first day study . In patient , serial measurement serum urine AZT metabolite , 3'-azido-3'-deoxy-5'-glucuronylthymidine ( GAZT ) , monitor dos .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed completion day 2 study : Prior medication may resume . Concurrent Treatment : Allowed completion day 2 study : Cytotoxic chemotherapy radiation therapy Kaposi 's sarcoma . The study divide three group cooperative patient accord mild , moderate , severe liver disease . Severity disease assess within 7 day entry study accord laboratory value . Patients must normal kidney function . No medication take 48 hour prior enter study . Hemophiliacs include . Prior Medication : Allowed : Zidovudine ( AZT ) discontinue least 48 hour prior study entry . Exclusion Criteria Coexisting Condition : Patients exclude study unacceptable toxicity develop illness require concurrent treatment develop . Concurrent Medication : Excluded within 48 hour study entry : All medication . Medication may resume completion day 2 study . Concurrent Treatment : Excluded within 48 hour study entry : All treatment . Treatment may resume completion day 2 study . Patients exclude follow reason : Presence active opportunistic infection , exception active chronic hepatitis B virus hepatitis D virus infection , ongoing therapy opportunistic infection . Thrombocytopenia , platelets less 50000 platelets/mm3 . Neutropenia , polymorphonuclear leukocytes less 1000 cells/mm3 . Renal insufficiency , creatinine great 1.5 mg/dl . Acute viral hepatitis within 30 day study . Patients expect noncompliant unwilling sign inform consent statement . Prior Medication : Excluded within 48 hour study entry : All medication . Medication may resume completion day 2 study . Prior Treatment : Excluded within 30 day study entry : Cytotoxic chemotherapy radiation therapy Kaposi 's sarcoma . Treatment may resume completion day 2 study . Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Liver</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Liver Function Tests</keyword>
	<keyword>HIV Seropositivity</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Biological Availability</keyword>
</DOC>